You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Naloxone Nasal Spray Development

    SBC: ANTIOP, INC.            Topic: NIDA

    DESCRIPTION: The following proposal is a follow-on Phase 2 b application from our initial proposal (1-R42 DA 030001). U.S. drug overdose deaths, mostly commonly from opioids, now exceed deaths from automobile accidents. There is a significant unmet medical need to provide additional pharmacologic options for treatment of opioid overdose. Emergency medical service personnel would prefer a non- inj ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. HUCBC modulation of Alzheimer's-like pathology and behavioral changes

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. A Home Exercise Program (DVD) for Women with Infants and Young Children

    SBC: KLEIN BUENDEL, INC            Topic: NIDA

    DESCRIPTION (provided by applicant): Becoming a mother is a significant transition in a woman's life. This transition can precipitate major changes in health behaviors, like physical activity. Once a woman has a child she is much less likely to participate in regular, moderate to vigorous physical activity compared to women without children. Thus, new mothers are at risk for future weight gain and ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. MyFAP: A Multimedia Intervention for Adolescents and Young Adults with FAP

    SBC: Radiant Creative Group, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): In this Phase II STTR application, we will build upon work conducted in our successful Phase I project which established the technical merit, acceptability and feasibility of developing a Web-based intervention, MyFAP.org, for adolescents and young adults (AYAs) with familial adenomatous polyposis (FAP). The main research goal of Phase II is to evaluate the eff ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Lactoferrin for Immunomodulation of Systemic Inflammatory Response Syndrome

    SBC: Pharmareview Corporation            Topic: NIGMS

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop a biologic therapeutic to treat systemic inflammatory response syndrome (SIRS) using a novel human recombinant lactoferrin that contains humanized glycosylation patterns. SIRS is a clinical expression of the action of complex acute-phase intrinsic mediators that precedes sepsis and subsequent tissue damage leadin ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  7. IYG-Family: Beyond the talk to effective pregnancy, STI, and HIV prevention

    SBC: Radiant Creative Group, LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): The goal of this 3 year Fast-Track STTR is to develop and evaluate a home-based intervention ('it's Your Game- Family') to provide age-appropriate sexual health life skills education and training for children (11-14 years) and to enhance parents' skills and self-confidence in support of this training. IYG-Family (IYG-F) will be an on-line g ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Optogenetic Multiparametric Assay for HT Cardiotoxicity Testing

    SBC: VALA SCIENCES, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Monitoring physiology of individual cardiomyocytes in high throughput has not been reported. The inability to perform high throughput physiological measurements limits many basic and applied studies, including the use of stem cell derived cardiomycoytes in cardiotoxicity testing. Current automated cardiotoxicity tests have poor predictive value because they use ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Multipurpose reversible terminators

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: NHGRI

    DESCRIPTION (provided by applicant): This Phase 2 STTR application will allow the Foundation for Applied Molecular Evolution (FfAME) to complete its transfer of technology to Firebird Biomolecular Sciences LLC, allowing Firebird to commercialize nucleoside triphosphates where the 3'-OH groups are blocked by a 3'-ONH2 group. Triphosphates having this modification are accepted by DNA polymerases and ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien

    SBC: MABVAX THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The carbohydrate antigen sialyl-Lewis a (sLea) is widely expressed on epithelial tumors of the gastrointestinal tract, on breast cancer cells, and also on small cell lung cancer cells but is expressed minimally or not at all on normal tissues. sLea serves as a ligand for epithelial leukocyte adhesion molecules and higher expression of sLea was observed in patie ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government